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Introduction: Several reports indicate that inflammation may play a role in depression and 
demonstrate enhanced systemic levels of inflammatory mediators. We hypothesized that 44 
patients with a diagnosis of depression would present with a specific and different serum and 
cerebrospinal fluid (CSF) cytokine profile compared to 21 patients with diffuse neurological 
symptoms, of whom 15 had fatigue as a major symptom, but no change in emotional state.
Methods: The diagnoses of the patients with depression were according to the International 
Classification of Diseases, tenth edition (F32–34 spectra). Cytokine profiles in serum and 
CSF were determined by multiplex analysis, including 27 cytokines, chemokines, and growth 
factors.
Results: No differences could be found between the two groups studied regarding cytokine 
levels in serum or CSF except for serum interleukin (IL)-1 receptor antagonist that was lower 
in the depression group. There were only four high correlations (.0.4) between serum and CSF 
levels of the cytokines, reflecting independent synthesis and turnover in these two compart-
ments. In the control group, fatigue was associated with increased IL-1 receptor antagonist, 
IL-10, granulocyte-colony stimulating factor, and interferon-γ (all P,0.01).
Conclusion: Patients with depression had a similar cytokine profile as nondepressive patients, 
both systemically and in CSF. Fatigue was associated with higher levels of some inflammatory 
markers in the control group. It is possible that the presence of fatigue in a large proportion 
of patients and controls could contribute to the lack of difference in cytokine levels between 
these two groups.
Keywords: depression, cytokines, chemokines, inflammation, fatigue, serum, CSF, multiplex 
analysis
Introduction
Depression is the most widespread mental disorder in the world as .350 million 
individuals suffer from the disorder worldwide.1 Three general mechanisms have 
been suggested to influence biomarkers related to depression, namely, through 
neurotransmitter signaling, the hypothalamic–pituitary–adrenal axis, and inflamma-
tion. Alterations in these interacting pathways also seem to play a pathogenic role in 
depressive disorders. As for inflammation, several lines of evidence support a role for 
activation of these pathways in the progression of depression. First, several studies 
have shown increased systemic levels of inflammatory cytokines and other inflam-
matory markers in patients with depression,2,3 and a recent gene expression study in a 
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large population of patients with major depression disorder 
revealed a marked regulation of inflammatory and immune-
related pathways.4 Second, in patients receiving treatment 
with cytokines or other immune modulators, a considerable 
proportion may develop symptoms of severe depression.5–7 
Finally, some anti-inflammatory drugs have been shown to 
exert antidepressive effects.8,9
Other disorders related to psychological disturbances 
such as chronic fatigue and fibromyalgia may also show signs 
of systemic inflammation even though they do not show any 
changed emotional state as in depression.10,11
Moreover, while several studies have examined plasma 
or serum levels of inflammatory markers in depressive dis-
orders, data on these markers in cerebrospinal fluid (CSF) 
are scarce.3 Finally, cytokines and inflammatory mediators 
operate in network, and while several studies3 have examined 
some standard inflammatory cytokines such as tumor necrosis 
factor and interleukin (IL)-6 in these patients, fewer have 
simultaneously examined a wide range of inflammatory and 
anti-inflammatory markers reflecting the cytokine network.
We hypothesized that patients with a diagnosis of depres-
sion would present with a specific and different serum and 
CSF cytokine network profile compared to patients with 
diffuse neurological symptoms, but with no change in the 
emotional state.
Materials and methods
Patients and controls
A group of depressed patients (n=49) were recruited from 
inpatient wards and outpatient clinics of the mental health 
unit at Innlandet Hospital Trust in the eastern part of Norway. 
They were all older than 18 years and had a diagnosis of 
depression according to the research criteria of International 
Classification of Diseases, tenth edition (F32–34 spectra) and 
Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition, text revision. Five of these patients were excluded 
because they were not able to give CSF sample for different 
reasons. The control group comprised 21 patients with neu-
rological symptoms referred to the Department of Neurology 
at the same hospital for thorough investigations. They all 
had a careful neurological examination, including computed 
tomography/magnetic resonance imaging scans and spinal 
fluid examination. None of them had any neurological signs of 
disease, and neither did any of them have any laboratory find-
ings indicating cerebral disease or disorder. Clinically, they 
had many of the same components as in depression, including 
tiredness, fatigue, lack of initiative, and a feeling that the body 
is not functioning, but without any overt signs of depression, 
ie, change in mood or emotional state. A medical history was 
recorded, a routine clinical examination was performed, and 
hematological and biochemical screening tests were carried 
out in all patients. None of the participants included in the 
study had any known comorbid disorders such as infection 
or inflammatory disorders that could influence the levels of 
cytokines. The data were collected between October 2010 
and December 2013 by the same personnel and handled and 
stored at the hospital laboratory.
Ethics
The study was approved by the Norwegian Regional Com-
mittees for Medical and Health Research Ethics. Written 
informed consent was given by all participants before 
inclusion.
Psychiatric and neuropsychological 
examination
All patients were examined with the Montgomery–Åsberg 
Depression Rating Scale (MADRS;12 no depression 0–6, 
mild depression 7–19, moderate depression 20–34, and 
severe depression .34), the Beck Depression Inventory-II 
(BDI-II;13–15 minimal depression 0–13, mild depression 
14–19, moderate depression 20–28, and severe depression 
29–63), and the Mini–Mental Status Examination (MMSE)16 
for cognitive functioning/dementia (score 0–30, normal $24). 
The participants were asked about fatigue in the clinical inter-
view, and questions about these symptoms are also one of 
the items on the BDI-II and MADRS.
collection of serum and csF
Peripheral blood was collected and allowed to clot for 
30 minutes before centrifugation for 10 minutes at 2,000× g. 
CSF samples were obtained by a trained neurologist and 
centrifuged within 30 minutes at 2,000× g for 10 minutes. 
Serum and CSF were aliquoted and stored at −70°C until 
analyses were performed. All blood samples were taken 
between 8.30 am and 10 am. The spinal tap was done before 
12 pm, except for two depressed patients who did the pro-
cedure closer to 1 pm. None of the patients were fasting as 
a prerequisite before blood or CSF sampling.
Multiplex analysis
The samples were analyzed according to the instructions from 
the manufacturer on a Multiplex Analyzer using a multiplex 
cytokine assay (Bio-Plex Human Cytokine 27-Plex Panel; 
Bio-Rad Laboratories Inc., Hercules, CA, USA) containing the 
following ILs, chemokines, and growth factors: IL-1β; IL-1 
receptor antagonist (IL-1Ra); IL-2; IL-4; IL-5; IL-6; IL-7; 
IL-8 (CXCL8); IL-9; IL-10; IL-12 (p70); IL-13; IL-15; IL-17; 
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eotaxin/CCL11; basic fibroblast growth factor; granulocyte-
colony stimulating factor (G-CSF); granulocyte macrophage 
CSF; interferon (IFN)-γ; IFN-inducible protein 10 (IP-10; 
CXCL10); monocyte chemoattractant protein 1 (MCP-1; 
CCL2); macrophage inflammatory peptide (MIP)-1α (CCL3); 
MIP-1β (CCL4); platelet-derived growth factor-BB; regulated 
on activation, normal T-cell expressed and secreted (RANTES; 
CCL5) tumor necrosis factor; and vascular endothelial growth 
factor. The inter- and intra-assay coefficients of variants were 
,12% for all 27 analytes, and based on years of experience 
with equal results for duplicates, the method is now standard-
ized for single measurement in our laboratory.
Serum samples for 25 of the analytes showed detectable 
values for 100% of the samples. For granulocyte macrophage 
CSF and RANTES, 97% and 93% of the samples, respec-
tively, were within detectable limits. CSF samples for 24 
of the analytes showed detectable values for .93% of the 
samples. For IL-12, IL-7, and G-CSF, 3%, 38%, and 89% of 
the samples, respectively, were within detectable limits.
statistical analysis
The characteristics of the patients were analyzed with descrip-
tive statistics and reported as exact number (percentages) or 
mean and standard deviation (SD). Comparisons between the 
groups were analyzed with an exact test for 2×2 tables and 
Student’s t-test with Levene’s test for equality of variance and 
adjusting for antidepressive and antipsychotic medication. 
Correlations were assessed with Spearman’s rho. Owing to 
multiple comparisons, P-values (two-sided) were considered 
to be significant when ,0.01.
Results
The characteristics of the participants with comparisons 
between the two groups of individuals are shown in Table 1. 
Compared to controls, the patients with depression had 
significantly higher scores on BDI-II and MADRS and 
lower score on MMSE. All participants except for one in the 
depression group (who had 23 score, which is just below the 
average score) scored in the normal range on MMSE.
cytokine levels in serum and csF
There were no significant differences between the two study 
groups with respect to cytokine levels in serum (Table 2). 
IL-1Ra showed a borderline significant result with a lower 
level for the depressed participants compared to the controls. 
Similarly, there were no differences between the two groups 
with respect to cytokine levels in CSF (Table 3).
severity of depression and cytokine levels
Among the patients with depression, there were no signifi-
cant associations between severity of symptoms measured 
Table 1 Demographic characteristics
Demographics, distinctive 
measurements, and 
medication
Neurological 
group
Depression 
group
P-value
age 47.9 (13.9) 44.7 (15.1) 0.41
sex (female/male) 14/7 23/21 0.27
MMsea 29.2 (1.0) 28.3 (1.8) 0.02
BDi-iia 6.5 (6.7) 31.1 (12.6) ,0.0001
MaDrsa 8.1 (5.9) 28.0 (8.0) ,0.0001
antidepressive drugs 1 (4.8%) 30 (68.2%) ,0.0001
antipsychotic drugs 0 (0%) 14 (31.8%) 0.004
Notes: age, MMse, BDi-ii, and MaDrs scores are reported as mean (sD), whereas sex 
and medication are expressed as the number of concerned individuals (% of the group). 
aTwo participants in the neurological group did not complete these examinations.
Abbreviations: MMse, Mini–Mental status examination; BD-ii, Beck Depression 
inventory-ii; MaDrs, Montgomery–Åsberg Depression rating scale; sD, standard 
deviation.
Table 2 comparison of the cytokine serum (pg/ml) levels for 
the two study groups
Cytokine Neurological group 
(mean, SD), N=21
Depression group 
(mean, SD), N=44
P-value*
il-1β 1.4 (0.2) 1.3 (0.3) 0.10
il-1ra 188 (41) 164 (42)a 0.01
il-2 4.9 (5.4) 3.5 (2.7)a 0.21
il-4 2.6 (0.5) 2.5 (0.5) 0.02
il-5 0.7 (0.1) 0.8 (0.9) 0.76
il-6 6.4 (1.7) 6.1 (2.3) 0.28
il-7 4.1 (1.4) 3.6 (1.4) 0.02
il-8 12 (2.9) 13 (3.0) 0.57
il-9 20 (5.6) 22 (10)a 0.30
il-10 4.4 (1.8) 3.5 (1.9) 0.05
il-12 p70 19 (10) 17 (9.9) 0.35
il-13 3.4 (1.7) 2.7 (0.7) 0.02
il-15 1.1 (0.5) 1.1 (0.9)a 0.20
il-17a 122 (35) 122 (32) 0.52
eotaxin 92 (49) 103 (76) 0.51
FgF-basic 52 (13) 53 (15) 0.96
g-csF 67 (17) 64 (20) 0.32
gM-csF 8.3 (4.6) 7.2 (5.0) 0.16
iFN-γ 61 (13) 55 (11) 0.09
iP-10 506 (244) 585 (316) 0.70
McP-1 40 (16) 36 (11) 0.06
MiP-1α 2.3 (0.5) 2.2 (0.9) 0.72
MiP-1β 117 (61) 129 (45) 0.96
PDgF-BB 4,090 (1,727) 3,756 (1,067) 0.21
raNTes 53,647 (32,113) 68,501 (122,517) 0.78
TNFα 31 (4.3) 30 (5.5) 0.07
VegF 45 (35) 41 (24) 0.24
Notes: aFor these cytokines, one participant with an extreme value (ie, .3 sD 
from mean) was excluded. *adjusted for use of antipsychotic and antidepressive 
medication.
Abbreviations: sD, standard deviation; il, interleukin; il-1ra, il-1 receptor 
antagonist; FGF, fibroblast growth factor; G-CSF, granulocyte-colony stimulating 
factor; gM-csF, granulocyte macrophage csF; iFN, interferon; iP-10, iFN-inducible 
protein 10; McP-1, monocyte chemoattractant protein 1; MiP-1, macrophage 
inflammatory peptide 1; PDGF-BB, platelet-derived growth factor-BB; RANTES, 
regulated on activation, normal T-cell expressed and secreted; TNF, tumor necrosis 
factor; VegF, vascular endothelial growth factor.
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with MADRS and BDI-II and serum cytokine levels. In 
CSF, severity of symptoms and IL-15 (BDI-II: ρ=−0.37, 
P=0.01; MADRS: ρ=−0.47, P=0.001) and MCP-1 (BDI-II: 
ρ=−0.54, P,0.001) were correlated. In CSF of the controls, 
IL-2 levels were correlated with the severity of symptoms 
(BDI-II [IL-2]: ρ=−0.63, P=0.004). On BDI-II, there is partly 
an overlap between depression symptoms and symptoms 
related to physical and psychological functions such as 
change in appetite, fatigue and tiredness, and concentration 
difficulty, which may also give elevated scores on MADRS 
or BDI-II in the control group even though the patients are 
not depressed.
Fatigue symptoms and cytokine levels
There was an overlap in symptoms between the two groups 
studied, especially related to fatigue. In the depressed group, 
42 of the 44 patients reported to experience fatigue to be part 
of the depression disorder. In the control group, 15 of the 
21 patients had fatigue.
These 15 with fatigue symptoms had significantly higher 
serum levels of IL-1Ra (P=0.010), IL-10 (P=0.004), G-CSF 
(P=0.006), and IFN-γ (P=0.004) than those without fatigue 
symptoms (n=6). In contrast, CSF values did not discriminate 
between those with fatigue and those without. As fatigue 
most probably is a part of the phenotype of depression, 
being present in 42 of the 44 patients with depression, we 
were precluded from doing a similar analysis in depressive 
patients.
correlations between cytokine levels in 
serum and csF
Within the control group, there was high correlation between 
eotaxin in serum and CSF (ρ=0.63, P=0.002). For the 
patients with depression, high correlations were seen for 
eotaxin (ρ=0.44, P=0.003), IP-10 (ρ=0.46, P=0.002), and 
MIP-1β (ρ=0.46, P=0.002). Otherwise, correlations were 
lower than 0.4.
Discussion
In contrast to our hypothesis that patients with major depres-
sion would present with a specific and different serum and 
CSF cytokine network profile compared to patients with 
diffuse neurological symptoms, we observed no differences 
in the levels of a wide range of cytokines in either serum or 
CSF between the two study groups, except for marginally 
lower levels of IL-1Ra in depressive patients. Furthermore, 
except for a few chemokines, relatively few correlations were 
found between serum and CSF suggesting limited interplay 
between these compartments in these individuals, with no dif-
ferences between depressive patients and controls. However, 
it must be emphasized that it is difficult to draw firm conclu-
sions from such a small sample size as in this study. Also, a 
limitation of the study is that some degree of intraindividual 
variability occurs in the methods used in the study. Therefore, 
repeated measurements over time are the best way to con-
trol such variations. Nevertheless, if it is difficult to obtain 
approval for one CSF sample, it would be very complicated 
to get multiple samples from the same individual. However, 
one cannot exclude that some physiological variability adds 
a layer of uncertainty to the pathological variation when 
measuring a single time point.
Based on the growing body of evidence demonstrating 
elevated systemic levels of proinflammatory cytokines and 
several chemokines in blood of depressed patients,3 it is 
surprising that we found no associations between systemic 
Table 3 Comparison of cytokine cerebrospinal fluid levels 
(pg/ml) for the two study groups
Cytokine Neurological group 
(mean, SD), N=21
Depression group 
(mean, SD), N=44
P-value*
il-1β 0.4 (1.1) 0.2 (0.3) 0.21
il-1ra 0.8 (0.3) 0.8 (0.3) 0.13
il-2 0.7 (0.4) 0.5 (0.4) 0.30
il-4 0.1 (0.1) 0.1 (0.1) 0.27
il-5 0.2 (0.1) 0.3 (0.4) 0.65
il-6 3.3 (1.3) 4.0 (3.2) 0.75
il-7a
il-8 36 (13) 38 (15) 0.49
il-9 3.3 (1.1) 3.3 (0.9) 0.21
il-10 1.6 (0.4) 1.5 (0.3) 0.40
il-12 p70a
il-13 4.6 (7.3) 5.8 (12) 0.70
il-15 5.4 (1.5) 5.4 (1.8) 0.57
il-17a 6.3 (3.9) 6.2 (3.7) 0.56
eotaxin 3.7 (5.7) 3.1 (8.5) 0.45
FgF-basic 7.0 (3.7) 6.0 (3.4) 0.34
g-csFa
gM-csF 45 (7.7) 45 (7.7) 0.69
iFN-γ 3.9 (9.0) 2.9 (8.1) 0.58
iP-10 670 (399) 693 (424) 0.50
McP-1 287 (130) 286 (116) 0.87
MiP-1α 1.0 (0.3) 1 (0.3) 0.29
MiP-1β 17 (6.6) 14 (4.7) 0.06
PDgF-BB 3.7 (2.7) 4.3 (3.9) 0.24
raNTes 2.7 (2.2) 3.6 (6.5) 0.13
TNFα 1.6 (0.9) 1.4 (0.8) 0.29
VegF 15 (5.5) 15 (5.4) 0.16
Notes: aThe levels of cytokines were below the lower detection limit. *adjusted for 
use of antipsychotic and antidepressive medication.
Abbreviations: IL, interleukin; IL-1Ra, IL-1 receptor antagonist; FGF, fibroblast 
growth factor; g-csF, granulocyte-colony stimulating factor; gM-csF, granulocyte 
macrophage csF; iFN, interferon; iP-10, iFN-inducible protein 10; McP-1, monocyte 
chemoattractant protein 1; MIP-1, macrophage inflammatory peptide 1; PDGF-BB, 
platelet-derived growth factor-BB; raNTes, regulated on activation, normal T-cell 
expressed and secreted; TNF, tumor necrosis factor; VegF, vascular endothelial 
growth factor.
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markers and severity of depressive symptoms in the serum 
of the patient group. However, whereas most previous 
studies (e.g. Hestad et al 2009)17 have compared inflamma-
tory serum markers in patients with depression and healthy 
controls, we in the present study examined these markers 
in both serum and CSF and included a control group with a 
certain degree of overlap in symptoms, especially related to 
fatigue, but without a depressive disorder. Several studies 
have demonstrated that depression and chronic fatigue and 
fibromyalgia share aberrations in inflammatory pathways,18 
and it is not inconceivable that this could have contributed 
to the lack of differences in cytokine levels between the two 
groups of individuals in the present study. It is possible that 
depression cannot be distinguished from patients who suffer 
from fatigue with respect to systemic or CSF values of inflam-
matory markers because a large proportion of the depressive 
patients also have similar symptoms. However, it is suggested 
that possible inflammatory processes seen in depression 
might be closely linked with multiple neurodegenerative 
pathways.19,20 Advanced aging and a number of risk factors 
such as obesity, hypertension, diabetes, and atherosclerosis 
could act as “silent contributors” promoting a chronic proin-
flammatory state. Brain reserves may have neuroprotective 
effects against late life depression.21 In our project, the study 
population was relatively young with a mean age of ~45 and 
no degenerative signs of sickness. It may be that a higher age 
and more comorbidity would have contributed to a higher 
level of inflammation among the depressed participants.
 A few studies have examined the cytokine level in CSF in 
patients with depression. Evidence has shown increased lev-
els of IL-1β22 and divergent results for IL-622,23 and MCP-1.24 
The last study was related to medication with IFN-α, while 
Lindqvist et al23 studied suicide attempters and normal con-
trols and Levine et al22 used patients who were evaluated for 
headache or suspended meningitis as controls. However, no 
studies have compared levels in CSF with systemic levels 
of inflammatory markers. Chemokines may enhance perme-
ability of the blood–brain barrier and increase neuroinflam-
mation by promoting infiltration of inflammatory cells.25 In 
general, we found few correlations .0.4 between the two 
compartments. However, our finding that eotaxin, IP-10, and 
MIP-1β showed a high correlation between the two compart-
ments could suggest a potential role for these chemokines in 
the regulation of neuroinflammation.
Strengths of our study include the case–control design 
where all the patients came from the same county, were 
examined at the same hospital, and had an overlap in some 
but not in all depressive symptoms. The multiplex assay 
gave us the opportunity to evaluate the inflammatory reaction 
broadly in both serum and CSF with an acceptable coefficient 
of variation. However, as there are no universal or official 
reference range values for the analyses used in the present 
study, the lack of a normal healthy population group is a limi-
tation of the present study with respect to comparison of the 
levels of the cytokines in these two groups with a reference 
population. A limitation of the study is that some degree of 
intraindividual variability occurs that repeated measurements 
over time could control for. However, this is not easily done 
regarding CSF where the method is somewhat more difficult 
than taking a blood sample. Finally, the subgroup analysis 
comparing the levels of inflammatory markers in controls 
with and without fatigue had small groups, and caution is 
needed when interpreting these results.
Conclusion
In conclusion, compared to patients with diffuse neurologi-
cal symptoms with fatigue as a major symptom, but with no 
change in the emotional state, patients with major depression 
did not display any major alterations in systemic or CSF 
levels of cytokines and growth factors. The general lack of 
correlation between serum and CSF suggests limited inter-
actions between the two compartments for the mediators 
investigated. Fatigue was associated with higher levels of 
some inflammatory markers, and it is possible that the pres-
ence of this symptom in a large proportion of patients and 
controls could contribute to the lack of difference in cytokine 
levels between these two groups.
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